Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026 6:44 AM EDTSurpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026Successfully completed oversubscribed $57.5 million public offering supported by both new and existing healthcare-focused investors
AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.
... More